SCHEMBL67130

SCHEMBL67130

NCCCc1nc(N)c2[nH]cnc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.54
GDA Q9Y2T3 1/20 0.54
PI4KA P42356 2/20 0.43
PI4K2B Q8TCG2 2/20 0.43
PI4K2A Q9BTU6 2/20 0.43
PI4KB Q9UBF8 2/20 0.43
LMNA P02545 1/20 0.43
DRD3 P35462 1/20 0.43
XDH P47989 1/20 0.43
LRRK2 Q5S007 1/20 0.43
POLA1 P09884 2/20 0.43
CDK2 P24941 6/20 0.40
DPP4 P27487 1/20 0.40
CDK1 P06493 6/20 0.39
CCNB1 P14635 6/20 0.39
CCNA2 P20248 5/20 0.39
CCNA1 P78396 5/20 0.39
PIN1 Q13526 1/20 0.39
PNP P00491 1/20 0.39
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29605437 1.00 PDPK1 (0.54) PDPK1GDAPI4KAPI4K2BPI4K2A
SCHEMBL1374742 0.94 PDPK1 (0.51) PDPK1GDAPI4KAPI4K2BPI4K2A
SCHEMBL38912 0.94 PDPK1 (0.51) PDPK1GDAPI4KAPI4K2BPI4K2A
SCHEMBL29808400 0.94 PDPK1 (0.51) PDPK1GDAPI4KAPI4K2BPI4K2A
SCHEMBL6379588 0.90 PDPK1 (0.58) PDPK1GDAPI4KAPI4K2BPI4K2A
SCHEMBL11222102 0.88 PDPK1 (0.63) PDPK1GDAPI4KAPI4K2BPI4K2A
SCHEMBL19746433 0.86 PDPK1 (0.53) PDPK1GDAPI4KAPI4K2BPI4K2A
SCHEMBL8537687 0.86 PDPK1 (0.53) PDPK1GDAPI4KAPI4K2BPI4K2A
SCHEMBL27128261 0.86 PDPK1 (0.53) PDPK1GDAPI4KAPI4K2BPI4K2A
SCHEMBL1074970 0.86 POLA1 (0.57) PDPK1GDAPI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2065 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013071079-A1 LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-05-16 WO claimed
WO-1995015983-A1 PROCESS FOR IMMOBILISING BIOMOLECULES AND AFFINITY LIGANDS ON POLYMER CARRIERS GLUESENKAMP KARL HEINZ (DE) 1995-06-15 WO claimed
US-20260138999-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS BRISTOL MYERS SQUIBB CO (US) 2026-05-21 US disclosed
WO-2026106956-A1 DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN MERCK SHARP & DOHME LLC (US) 2026-05-21 WO disclosed
US-12629412-B2 Betacoronavirus mRNA vaccines MODERNATX, INC. (US) 2026-05-19 US disclosed
WO-2026098737-A1 NUCLEIC ACID CONJUGATE AND PHARMACEUTICAL COMPOSITION FOR LIPID DELIVERY, AND USE THEREOF 苏州时安生物技术有限公司 2026-05-15 WO disclosed
WO-2026102123-A1 SEQUENCE CAPTURE TECHNOLOGY AND PROBE DESIGN MONSANTO TECHNOLOGY LLC (US) 2026-05-15 WO disclosed
CN-122038302-A Modified T cells and methods of making and using the same 哈佛学院校长同事会 2026-05-15 CN disclosed
US-20260132405-A1 Modulation of Apolipoprotein C-III (ApoCIII) Expression in Lipoprotein Lipase Deficient (LPLD) Populations IONIS PHARMACEUTICALS, INC. (US) 2026-05-14 US disclosed
US-20260132404-A1 MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS ALNYLAM PHARMACEUTICALS, INC. (US) 2026-05-14 US disclosed
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF ADVANCED RNA VACCINE ARV TECH INC (US) 2026-05-14 US disclosed
US-20050164209-A1 Hepatocyte free uptake assays ISIS PHARMACEUTICALS, INC. 2005-07-28 US disclosed
US-20050080246-A1 Compositions comprising alternating 2'-modified nucleosides for use in gene modulation IONIS PHARMACEUTICALS, INC. 2005-04-14 US disclosed
WO-2005013901-A2 OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS ISIS PHARMACEUTICALS, INC. (US) 2005-02-17 WO disclosed
US-20050026160-A1 Compositions comprising alternating 2'-modified nucleosides for use in gene modulation IONIS PHARMACEUTICALS, INC. 2005-02-03 US disclosed
WO-2004044136-A2 COMPOSITIONS COMPRISING ALTERNATING 2’-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION ISIS PHARMACEUTICALS, INC. (US) 2004-05-27 WO disclosed
US-6602692-B1 Reacting a water insoluble matrix having amino groups such as membranes, resins, microtiter plates, with an activating cyclobutene such as 1,2-diethoxycyclobut-1-en-3,4-dione and then incubating with an amino-functional protein GLUESENKAMP KARL-HEINZ (DE) 2003-08-05 US disclosed
WO-2003008550-A2 SYNTHESIS OF OLIGONUCLEOTIDES ON SOLID SUPPORTS INCLUDING NON-REACTIVE SOLID DILUENTS ISIS PHARMACEUTICALS, INC. (US) 2003-01-30 WO disclosed
EP-1137658-A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES ISIS PHARMACEUTICALS, INC. (US) 2001-10-04 EP disclosed
WO-2000034303-A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR α-INDUCED EXPRESSION OF CELL ADHESION MOLECULES ISIS PHARMACEUTICALS, INC. (US) 2000-06-15 WO disclosed